The Egyptian Journal of Internal Medicine

Table 3 Clinical findings among studied patients

From: The efficacy and safety of niacin on hyperphosphatemia in ESRD patients undergoing hemodialysis: randomized controlled trial

	Niacin group (n = 25)	Control group (n = 25)	P value
Itching
Baseline	23 (92%)	22 (88%)	0.51
At 3rd month	3 (12%)	12 (48%)	< 0.001
At 6th month	2 (8%)	10 (40%)	< 0.001
Symptoms of MBD
Baseline	16 (64%)	17 (68%)	0.50
At 3rd month	15 (60%)	17 (68%)	0.45
At 6th month	13 (52%)	15 (60%)	0.11

Data expressed as frequency (percentage). P value was significant if < 0.05. MBD mineral bone disease

Back to article page